A systematic review of 177 studies found that specific peptides derived from food sources, particularly from plant and marine proteins, can inhibit ACE (an enzyme involved in blood pressure regulation) in laboratory and animal models . However, well-designed human trials remain absent, making it premature to claim functional food applications as established.
Researchers conducting this PRISMA-compliant systematic review synthesized evidence on bioactive peptides derived from food between January 2020 and January 2025. The scope was deliberately broad, capturing peptides from plant sources (including legumes and grains), marine organisms, insects, fungi, dairy, and terrestrial animals. Out of 177 included studies, approximately 72% focused on plant and marine matrices, suggesting these represent the most researched categories for antihypertensive peptide discovery.
The review identified a consistent research pipeline across studies: researchers began with in silico screening (computational prediction of which peptide sequences might inhibit ACE), then validated promising candidates through in vitro enzymatic assays, assessed intestinal transport using Caco-2 cell models, conducted ex vivo tissue experiments, and finally tested efficacy in spontaneously hypertensive rats (SHR). This multistage approach strengthens the plausibility that certain peptides can modulate blood pressure through ACE inhibition and related vascular mechanisms. The authors note that the most studied peptides were low-molecular-weight compounds (less than 3 kilodaltons), which theoretically have better absorption potential than larger protein fragments.
A key finding concerned bioavailability and stability challenges. Many food-derived peptides are susceptible to degradation during digestion and transport across the intestinal barrier. However, several studies demonstrated that encapsulation strategies and advanced delivery systems (microencapsulation, nanoparticles, and liposomal formulations) improved both stability and bioavailability in experimental settings. This suggests that formulation approach may be critical for translating bench-level activity into physiological effect.
Despite this body of mechanistic and animal evidence, the reviewers identified a substantial gap: the absence of well-designed, adequately powered human randomized controlled trials. While the evidence supports ACE-inhibitory potential in controlled laboratory environments and animal models, translation to human efficacy remains unproven. The authors explicitly called for greater methodological standardization, formal risk-of-bias assessment in primary studies, and human trials before making confident functional food claims.
This review clarifies that "antihypertensive peptide" research is fundamentally exploratory rather than clinically established. If you have elevated blood pressure, the evidence does not yet support replacing conventional treatment with peptide-enriched foods or supplements. The studied peptides come from everyday protein sources (milk, fish, legumes, nuts), so consuming adequate protein is reasonable on general nutritional grounds, but this is distinct from claiming antihypertensive benefit.
The research suggests that future functional foods or nutraceuticals incorporating these peptides may emerge, but they will require rigorous human validation before credible health claims can be made. If you see marketing language about "bioactive peptides for blood pressure," ask whether the claim is backed by human trials (most commonly, it is not). The animal and cell-based evidence is a necessary starting point, not an endpoint for product efficacy.
For those interested in evidence-supported dietary approaches to blood pressure, better-established strategies include high-fiber diet, potassium-rich foods, sodium reduction, and regular physical activity. These have documented human evidence and should remain the foundation of dietary blood pressure management.
| Attribute | Details |
|---|---|
| Study type | Systematic review and synthesis (PRISMA 2020) |
| Time period covered | January 2020 to January 2025 |
| Studies included | 177 peer-reviewed original research articles |
| Primary sources | Plant, marine, insect, fungal, dairy, terrestrial animal proteins |
| Key outcome assessed | ACE inhibition, vascular mechanisms, bioavailability, animal efficacy |
| Sample focus | Low-molecular-weight peptides (<3 kDa) |
| Major gap identified | Absence of randomized controlled trials in humans |
| Journal | Molecules (Basel, Switzerland) |
| PMID | 42197202 |
Systematic Review: Food-Derived Antihypertensive Peptides (2025)
https://pubmed.ncbi.nlm.nih.gov/42197202/
Note on evidence grading: This review represents evidence for ACE-inhibitory mechanisms in controlled laboratory and animal models. Translation to human blood pressure reduction remains (preclinical/animal only). No human efficacy trials are reported in the abstract or expected to be included given the review's 2020-2025 timeframe and its focus on mechanistic validation.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.